Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection
(Adnkronos) – Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE, N.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage
